So Far So Good: With Phase III Data, Keryx Says Zerenex Will Stand Out In ESRD Crowd
This article was originally published in The Pink Sheet Daily
Executive Summary
Company set to price drug up to 20% below Genzyme's market leading Renvela/Renagel franchise, and ponders impact of new Medicare bundling regime for phosphate binders used in end-stage renal disease.